{
 "name": "藥祇",
 "slug": "tw-7878",
 "aliases": [
  "藥祇生醫股份有限公司",
  "PHARMASAGA",
  "7878"
 ],
 "ticker": "7878",
 "industry": "生技醫療業",
 "website": "https://www.pharmasaga.com",
 "summary": "藥祇（7878）是興櫃的生技醫療類股公司，2021 年成立，2025 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "藥祇生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "PHARMASAGA",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2025-11-27",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2021-01-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "楊文欽",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "吳月禎",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 561365800,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.pharmasaga.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：PS1（糖尿病小分子）",
   "value": "第二型糖尿病｜第1期已完成｜台灣",
   "unit": "",
   "as_of": "2026-07-07",
   "source": "https://clinicaltrials.gov/study/NCT05176210",
   "note": "NCT05176210；申辦者 Pharmasaga Co. Ltd.；登錄 actual study completion 2026-06-05；適應症與開發階段不代表上市許可。"
  },
  {
   "claim": "管線：PS1（第一型糖尿病）",
   "value": "新診斷第一型糖尿病｜第2期已登錄、尚未收案｜地區未揭露",
   "unit": "",
   "as_of": "2026-10-22",
   "source": "https://clinicaltrials.gov/study/NCT07889505",
   "note": "NCT07889505；健康志願者 Part A 及新診斷 T1D 患者 Part B；登錄未列試驗中心地區，不推定為美國或台灣。"
  },
  {
   "claim": "催化劑：PS1",
   "value": "NCT07889505 第2期試驗預計開始｜2026-11-21（登錄估計）｜已公告",
   "unit": "",
   "as_of": "2026-10-22",
   "source": "https://clinicaltrials.gov/study/NCT07889505",
   "note": "NCT07889505；Start Date (Estimated)，不表示實際收案或核准已完成。"
  },
  {
   "claim": "管線：PS1（第二型糖尿病；美國二期）",
   "value": "第二型糖尿病｜第2期 IND 已送交美國 FDA｜美國",
   "unit": "",
   "as_of": "2026-10-01",
   "source": "https://www.pharmasaga.com/l/ps1-2-fda-ind/",
   "note": "公司獨立公告頁全文標 2026-10-01；試驗計畫 PS1-II-201；依公司 10/1 重大訊息完成 IND 送件，沒有宣稱 FDA 已核准。"
  },
  {
   "claim": "管線：PS1（第一型糖尿病；美國二期IND）",
   "value": "第一型糖尿病｜第2期 IND 已送交美國 FDA｜美國",
   "unit": "",
   "as_of": "2026-10-10",
   "source": "https://www.pharmasaga.com/l/ps1-1-fda-ind/",
   "note": "與 NCT07889505 未收案事實分開。公司獨立公告頁發布 2026-10-10，內文引用 10/9 重大訊息；試驗計畫 PS1-I-201。若 root 使用 MOPS 原公告，as_of 應依該原公告發布日，不以官網次日上稿日覆蓋。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-7878.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}